Pfizer to acquire Array BioPharma for $11.4bn

US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pfizer off-patent division to merge with Mylan

29 July 2019 Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

Americas

Alphabet's Verily in digital research alliance with Pfizer and others

22 May 2019 Verily, which is a subsidiary of Google’s parent company Alphabet, yesterday announced that it had partnered with Novartis, Otsuka, Pfizer, and Sanofi in efforts to develop digitally-innovative clinical research programmes.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Pfizer to acquire Array BioPharma for $11.4bn

More on this story

Editor's picks

Editor's picks

More features